Tuesday, July 28, 2015

Report: Endo Health Solutions in talks to be taken over

Endo Health Solutions has talked in recent weeks with other pharmaceutical companies about buying the Chadds Ford-based drugmaker, Reuters reported Wednesday.

Report: Endo Health Solutions in talks to be taken over

0 comments

Endo Health Solutions has talked in recent weeks with other pharmaceutical companies about buying the Chadds Ford-based drugmaker, Reuters reported Wednesday.

A link to the Reuters story is here.

The talks involved Warner Chilcott Plc and Valeant Pharmaceuticals International Inc., Reuters reported, citing sources it did not identify.

In an email to the Inquirer, Endo spokesman Kevin Wiggins said, "As a matter of company policy, we do not comment on market speculation."

Endo's top products are painkillers and it faces regulatory issues and generic competition. The company's Lidoderm patch and Opana ER tablets are among its best-selling products, but both will soon have generic competition. With the rise in deaths due to overdoses of prescription painkillers, government agencies have looked more closely at how drug companies and their wholesalers make and distribute those medicines.

In December, Endo chief executive officer Dave Holveck announced he would retire this year. The company has been planning to move into a new headquarters in Malvern.

Warner Chilcott is headquartered in Ireland but its main U.S. office is in Rockaway, N.J.

Valeant is headquartered in Montreal, with its U.S. headquarters in Bridgewater, N.J. In 2011, Valeant mounted a public - and eventually unsuccessful - challenge to Teva Pharmaceuticals' purchase of Frazer-based Cephalon.

 

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter